Laura A. Ekas, Ph.D.

Laura A. Ekas's Education and Expertise

Laura A. Ekas, Ph.D., has a robust academic background in the sciences. She earned her Bachelor of Arts degree in behavioral biology from the prestigious Johns Hopkins University. Her academic journey continued at the New York University School of Medicine, where she obtained a Ph.D. in pharmacology and signal transduction. This combination of behavioral biology and pharmacology provides her with a unique perspective on both the physiological and psychological aspects of healthcare. Her extensive education has equipped her with the expertise necessary to navigate complex scientific and medical landscapes, making her a valuable asset in the biotech and pharmaceutical industries.

Laura A. Ekas's Career at Alexion Pharmaceuticals

During her tenure at Alexion Pharmaceuticals, Laura A. Ekas focused on several critical areas including global pricing and reimbursement, corporate operations, and investor relations. Her role involved developing strategies to ensure that Alexion's innovative therapies were accessible to patients worldwide while also maintaining corporate sustainability and investor confidence. Her work at Alexion highlights her expertise in navigating the complex regulatory and financial aspects of the pharmaceutical industry, showcasing her ability to balance business objectives with patient needs.

Laura A. Ekas's Role at Insight Strategy Advisors

As a Consultant at Insight Strategy Advisors, Laura A. Ekas specialized in patient access, pricing, and supply chain strategies. Her role required her to develop and implement strategies that ensured patients could access necessary treatments while also addressing the economic considerations of healthcare providers and pharmaceutical companies. This position allowed her to leverage her scientific background in a business context, demonstrating her versatility and ability to impact both the scientific and commercial aspects of the healthcare industry.

Laura A. Ekas's Positions at Canaccord Genuity Group

Laura A. Ekas held several positions of increasing responsibility at Canaccord Genuity Group, culminating in her role as Vice President of Biotech Equity Research. In this capacity, she conducted in-depth analyses of biotech companies, providing critical insights to investors about the potential and risks associated with biotech investments. Her work involved evaluating scientific data, understanding market dynamics, and forecasting financial outcomes. This role underscored her ability to translate complex scientific information into actionable financial strategies, benefiting both the companies she analyzed and the investors she advised.

Laura A. Ekas's Personal Interests and Philanthropy

Outside of her professional life, Laura A. Ekas has a passion for travel, with Rome being her favorite city to visit. Her connection to the city is likely influenced by its rich history and vibrant culture, which provides a stark contrast to her scientific pursuits. Additionally, she is a supporter of the Michael Mosier Defeat DIPG Foundation, an organization dedicated to finding a cure for diffuse intrinsic pontine glioma (DIPG). This involvement reflects her commitment to philanthropy and her desire to contribute to causes that have a significant impact on patients' lives. Despite growing up in Virginia, she considers herself a New Yorker at heart, indicating her deep connection to the bustling, dynamic environment of New York City.